Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to ...

Dren Bauta returned to school in February after missing nine months. He credits his determination to rejoin his football team as a major motivation. MONTVALE – Dren Bauta couldn’t swallow blueberries.

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

Dren Bio, a privately held, US clinical-stage biotechnology company developing first-in-class myeloid cell engager therapeutics, announced today that it has entered into a strategic collaboration with ...

Under the agreement, Dren Bio will receive an upfront payment of $100 million and could earn up to $1.7 billion in additional development, regulatory, and commercial milestone payments. The deal ...

Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in undisclosed inflammatory indications. After buying Dren Bio’s B cell depletion ...